Mavacamten FDA Approval Status
FDA Approved: No
Generic name: mavacamten
Company: Bristol-Myers Squibb Company
Treatment for: Hypertrophic Cardiomyopathy
Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin in development for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Development Timeline for mavacamten
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.